H. Eldar-Finkelman

发表

VIVO AND IN VITRO STUDIES IN in the Alzheimer Disease Mouse Model : Mammalian Target of Rapamycin Activity Restores Lysosomal Acidification and -Amyloid Pathology and β Ameliorates Inhibition of Glycogen Synthase Kinase-3 Molecular Bases of Disease:

H. Eldar-Finkelman, R. Vassar, L. Avrahami, 2013 .

Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model

H. Eldar-Finkelman, R. Vassar, L. Avrahami, 2012, The Journal of Biological Chemistry.

New Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3 β

S. Pietrokovski, M. Eisenstein, H. Eldar-Finkelman, 2008 .

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Peptide inhibitors targeting protein kinases.

M. Eisenstein, H. Eldar-Finkelman, 2009, Current pharmaceutical design.

Inactivation of Glycogen Synthase Kinase-3 by Epidermal Growth Factor Is Mediated by Mitogen-activated Protein Kinase/p90 Ribosomal Protein S6 Kinase Signaling Pathway in NIH/3T3 Cells (*)

E. Krebs, R. Seger, H. Eldar-Finkelman, 1995, The Journal of Biological Chemistry.

Lithium-mediated phosphorylation of glycogen synthase kinase-3β involves PI3 kinase-dependent activation of protein kinase C-α

H. Eldar-Finkelman, O. Kaidanovich‐Beilin, Noa Kirshenboim, 2007, Journal of Molecular Neuroscience.

Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas.

H. Eldar-Finkelman, B. Schmidt, Fabio Lo Monte, 2011, Bioorganic & medicinal chemistry letters.

Substrate competitive GSK-3 inhibitors - strategy and implications.

S. Pietrokovski, M. Eisenstein, H. Eldar-Finkelman, 2010, Biochimica et biophysica acta.

Leptin Induces Insulin-like Signaling That Antagonizes cAMP Elevation by Glucagon in Hepatocytes*

E. Krebs, J. Beavo, K. Bornfeldt, 2000, The Journal of Biological Chemistry.

The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes

H. Eldar-Finkelman, Oksana Kaidanovich, 2002, Expert opinion on therapeutic targets.

Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3

H. Eldar-Finkelman, Batya Plotkin, Ilana Talior, 2003, Journal of Pharmacology and Experimental Therapeutics.

Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.

E. Krebs, H. Eldar-Finkelman, M. Shinohara, 1999, Diabetes.

Insulin Resistance and Glycogen Synthesis: Roles in Liver, Muscle and Adipose Tissue

H. Eldar-Finkelman, Merav Yarkoni, M. Yarkoni, 2002 .

GSK-3 inhibition: achieving moderate efficacy with high selectivity.

M. Eisenstein, H. Eldar-Finkelman, L. Avrahami, 2013, Biochimica et biophysica acta.

Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.

M. Eisenstein, H. Eldar-Finkelman, Batya Plotkin, 2011, Journal of molecular biology.

GSK-3β Inhibition in Birds Affects Social Behavior and Increases Motor Activity

J. Terkel, H. Eldar-Finkelman, A. Barnea, 2022, Frontiers in Physiology.

Monitor and Molecules.

D. Gurwitz, H. Eldar-Finkelman, 2001, Drug discovery today.

Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta.

H. Eldar-Finkelman, J. Chatham, G. Gibbons, 2001, Diabetes.

Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.

M. Pardo, M. Faghihi, R. Jope, 2017, JCI insight.

Autoimmune Encephalomyelitis by Glycogen Regulation of Th1 Cells and Experimental

L. Harrington, R. Jope, Ling Song, 2013 .

GSK-3β Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds

H. Eldar-Finkelman, A. Barnea, E. Aloni, 2015, Brain, Behavior and Evolution.

Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action.

E. Krebs, H. Eldar-Finkelman, Edwin G. Krebs, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice.

H. Eldar-Finkelman, N. Bashan, Merav Yarkoni, 2003, American journal of physiology. Endocrinology and metabolism.

Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle

H. Eldar-Finkelman, O. Kaidanovich‐Beilin, 2006, Journal of Pharmacology and Experimental Therapeutics.

GSK-3 and lysosomes meet in Alzheimer’s disease

H. Eldar-Finkelman, L. Avrahami, 2013, Communicative & integrative biology.

Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition

R. Jope, H. Eldar-Finkelman, S. Grieco, 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Exploiting substrate recognition for selective inhibition of protein kinases.

H. Eldar-Finkelman, Avital Licht-Murava, 2012, Current pharmaceutical design.

Distinct Molecular Regulation of Glycogen Synthase Kinase-3α Isozyme Controlled by Its N-terminal Region

S. Pietrokovski, J. Jaworski, H. Eldar-Finkelman, 2011, The Journal of Biological Chemistry.

Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy

H. Eldar-Finkelman, Ido Rippin, Sara Melisa Arciniegas Ruiz, 2022, Cells.

Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha.

H. Eldar-Finkelman, O. Kaidanovich‐Beilin, Noa Kirshenboim, 2004, Journal of molecular neuroscience : MN.

Structure-based optimization of oxadiazole-based GSK-3 inhibitors.

H. Eldar-Finkelman, B. Schmidt, A. Fuertes, 2013, European journal of medicinal chemistry.

Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.

E. Novellino, A. Coluccia, A. Brancale, 2013, Journal of medicinal chemistry.

Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site

H. Senderowitz, N. Khazanov, H. Eldar-Finkelman, 2020, International journal of molecular sciences.

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

Ana Martínez, H. Eldar-Finkelman, 2011, Front. Mol. Neurosci..

Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3

H. Eldar-Finkelman, A. Pinhasov, G. Agam, 2010, Molecular and Cellular Neuroscience.

Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.

E. Novellino, H. Eldar-Finkelman, F. van Leuven, 2012, Journal of medicinal chemistry.

Glycogen synthase kinase 3: an emerging therapeutic target.

H. Eldar-Finkelman, Hagit Eldar-Finkelman, 2002, Trends in molecular medicine.

Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1.

Yanbin Zheng, H. Eldar-Finkelman, C. Rhodes, 2010, The Journal of endocrinology.

proteasome degradation of insulin receptor substrate-1

Yanbin Zheng, H. Eldar-Finkelman, Wenshuo Zhang, 2010 .

AUTHOR COPY ONLY Glycogen synthase kinase 3b mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1

Yanbin Zheng, H. Eldar-Finkelman, C. Rhodes, 2010 .

Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling*

H. Eldar-Finkelman, Ziva Liberman, 2005, Journal of Biological Chemistry.

Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth

H. Eldar-Finkelman, L. Avrahami, A. Katz, 2014, Oncogene.

The SIL gene is essential for mitotic entry and survival of cancer cells.

M. Perelman, I. Kirsch, L. Trakhtenbrot, 2007, Cancer research.

Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3

J. Woodgett, L. Harrington, R. Jope, 2013, The Journal of Immunology.

Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β‐peptide

E. Melamed, D. Offen, H. Eldar-Finkelman, 2011, Journal of neurochemistry.

Overexpression of Protein Kinase C α in Swiss/3T3 Cells Reduces The Number of Both High and Low Affinity of the Epidermal Growth Factor Receptors

A. Ullrich, H. Eldar-Finkelman, E. Livneh, 1991 .

A unique type of GSK-3 inhibitor brings new opportunities to the clinic

M. Eisenstein, H. Eldar-Finkelman, L. Avrahami, 2016, Science Signaling.

Distinct Molecular Regulation of Glycogen Synthase Kinase-3α Isozyme Controlled by Its N-terminal Region

S. Pietrokovski, J. Jaworski, H. Eldar-Finkelman, 2011, The Journal of Biological Chemistry.

Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment

H. Eldar-Finkelman, Ronit Ilouz, 2003, Expert opinion on investigational drugs.

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

H. Eldar-Finkelman, Sara Melisa Arciniegas Ruiz, 2022, Frontiers in Molecular Neuroscience.

New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta.

S. Pietrokovski, M. Eisenstein, H. Eldar-Finkelman, 2008, Journal of molecular biology.

Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration

H. Eldar-Finkelman, Ido Rippin, 2021, Cells.

Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells.

E. Krebs, O. Foord, E. Fischer, 1996, Proceedings of the National Academy of Sciences of the United States of America.

PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase.

Toshio Kuroki, T. Kuroki, H. Eldar-Finkelman, 2005, American journal of physiology. Endocrinology and metabolism.

Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling.

H. Eldar-Finkelman, H. Sharfi, Hadar Sharfi, 2008, American journal of physiology. Endocrinology and metabolism.

Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury

H. Eldar-Finkelman, E. Shohami, A. Milman, 2007, Molecular and Cellular Neuroscience.

Selective loss of glycogen synthase kinase‐3α in birds reveals distinct roles for GSK‐3 isozymes in tau phosphorylation

S. Pietrokovski, J. Woodgett, H. Eldar-Finkelman, 2011, FEBS letters.

Identification of Novel Glycogen Synthase Kinase-3β Substrate-interacting Residues Suggests a Common Mechanism for Substrate Recognition*

M. Eisenstein, N. Kowalsman, H. Eldar-Finkelman, 2006, Journal of Biological Chemistry.

Peptides targeting protein kinases: strategies and implications.

H. Eldar-Finkelman, O. Kaidanovich‐Beilin, 2006, Physiology.

Implications Peptides Targeting Protein Kinases : Strategies and

H. Eldar-Finkelman, O. Kaidanovich‐Beilin, 2006 .

GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways.

C. Bucci, H. Eldar-Finkelman, L. Avrahami, 2020, Cellular signalling.

Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease

H. Eldar-Finkelman, Ido Rippin, Lilach Vaks, 2021, Neurobiology of Disease.

Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII.

E. Krebs, E. Fischer, R. Seger, 1994, The Journal of biological chemistry.

An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination

Y. Tabach, Carmit Levy, M. Khaled, 2022, Cancer research.

GSK3β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer

T. Giordano, E. Fearon, G. Bommer, 2010 .

GSK 3 β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer 1

T. Giordano, E. Fearon, G. Bommer, 2010 .

Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue.

H. Eldar-Finkelman, T. Tennenbaum, Batya Plotkin, 2008, American journal of physiology. Endocrinology and metabolism.

Regulation of Ribosomal S6 Protein Kinase-p90rsk, Glycogen Synthase Kinase 3, and β-Catenin in Early Xenopus Development

Randall T. Moon, E. Krebs, R. Moon, 1999, Molecular and Cellular Biology.

Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc.

D. Gurwitz, H. Eldar-Finkelman, Ronit Ilouz, 2002, Biochemical and biophysical research communications.

Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus

Abraham Weizman, H. Eldar-Finkelman, O. Kaidanovich‐Beilin, 2004, Biological Psychiatry.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.

T. Giordano, E. Fearon, G. Bommer, 2010, Neoplasia.

ATM signaling delays skin pigmentation upon UV exposure by mediating MITF function towards DNA repair mode.

R. Elkon, Y. Shiloh, G. Ast, 2023, The Journal of investigative dermatology.

Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner

H. Eldar-Finkelman, A. Zilberberg, R. Rosin-Arbesfeld, 2008, Oncogene.

Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006

Leslie G. Ungerleider, D. Amit, H. Seung, 2006, Neural Plasticity.

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS

J. Woodgett, Ana Martínez, H. Eldar-Finkelman, 2011, Front. Mol. Neurosci..

Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice

H. Eldar-Finkelman, L. Avrahami, D. Farfara, 2023, Journal of Neuroinflammation.

Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3

M. Faghihi, R. Jope, H. Eldar-Finkelman, 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth

H. Eldar-Finkelman, L. Avrahami, A. Katz, 2014, Oncogene.

Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner

H. Eldar-Finkelman, A. Zilberberg, R. Rosin-Arbesfeld, 2008, Oncogene.

Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley.

H. Eldar-Finkelman, 2006, Expert opinion on therapeutic targets.

Glycogen synthase kinase 3: an emerging therapeutic target.

H. Eldar-Finkelman, 2002, Trends in molecular medicine.

Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue.

H. Eldar-Finkelman, T. Tennenbaum, Batya Plotkin, 2008, American journal of physiology. Endocrinology and metabolism.

GSK-3 inhibition: achieving moderate efficacy with high selectivity.

M. Eisenstein, H. Eldar-Finkelman, L. Avrahami, 2013, Biochimica et biophysica acta.

Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process

H. Eldar-Finkelman, R. Rosin-Arbesfeld, M. Caspi, 2023, PLoS Biology.

Correction: Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process

H. Eldar-Finkelman, R. Rosin-Arbesfeld, M. Caspi, 2024, PLoS biology.